August 25, 2026
For people living with obesity and obstructive sleep apnea, managing both conditions can sometimes feel like treating two separate problems. Now, research suggests that tirzepatide may help address both at the same time.
In December 2024, the U.S. Food and Drug Administration approved tirzepatide under the brand name Zepbound for adults with obesity who have moderate to severe obstructive sleep apnea. It is used along with a reduced calorie diet and increased physical activity. This made tirzepatide the first medication specifically approved by the FDA for this type of sleep apnea.
But what does this mean for someone who has sleep apnea? Can tirzepatide actually make breathing during sleep better?
Obstructive sleep apnea happens when the upper airway becomes blocked repeatedly while a person is sleeping. These blockages can cause breathing to stop and start throughout the night.
Obesity is an important risk factor for obstructive sleep apnea. Excess tissue around the neck and upper airway can make it easier for the airway to become narrowed or blocked during sleep.
This is one reason weight management can be an important part of sleep apnea care. However, losing weight does not automatically mean that sleep apnea will disappear. Some people continue to have sleep apnea even after losing a significant amount of weight.
This is why treatment should be based on the person's actual sleep apnea diagnosis and overall health rather than weight alone.
One of the most important studies was the SURMOUNT OSA clinical trial, published in the New England Journal of Medicine in 2024.
The researchers studied adults who had both obesity and moderate to severe obstructive sleep apnea. The study included people who were not using positive airway pressure therapy as well as people who were already using it.
After 52 weeks, people who received tirzepatide had a substantial reduction in their apnea hypopnea index, commonly called AHI. The AHI measures how many times a person experiences an apnea or hypopnea during an hour of sleep.
Among participants who were not using positive airway pressure therapy, the average AHI decreased by about 25 events per hour with tirzepatide, compared with about 5 events per hour with placebo.
Among participants who were already using positive airway pressure therapy, the average AHI decreased by about 29 events per hour with tirzepatide, compared with about 6 events per hour with placebo.
The study also found improvements in body weight, the amount of time participants experienced low oxygen levels during sleep, blood pressure, inflammation markers, and reported sleep related problems.
These findings are important because they suggest that the benefits of tirzepatide may extend beyond weight loss for people with obesity and obstructive sleep apnea.
The exact relationship between tirzepatide and sleep apnea is still being studied, but weight loss appears to be an important part of the explanation.
As body weight decreases, there may be less pressure and tissue around the upper airway. This can make it easier for the airway to remain open during sleep.
The SURMOUNT OSA trials showed that tirzepatide was associated with both weight loss and improvements in sleep apnea measurements. The medication may therefore help reduce some of the physical factors that contribute to airway obstruction.
However, it is important not to assume that the more weight a person loses, the more their sleep apnea will improve. Sleep apnea is influenced by several factors, including anatomy, age, airway structure, sleep position, and other health conditions.
Not necessarily.
This is one of the most important things to understand about tirzepatide and sleep apnea.
Positive airway pressure therapy, including CPAP, remains an important treatment for obstructive sleep apnea. The American Academy of Sleep Medicine recommends positive airway pressure therapy for adults with obstructive sleep apnea in appropriate circumstances, particularly when symptoms such as excessive daytime sleepiness are present.
The fact that tirzepatide may improve sleep apnea does not mean that a person should stop using CPAP on their own.
If someone loses weight while taking tirzepatide, their sleep apnea may change. A healthcare provider can determine whether additional testing is needed to see if the severity of sleep apnea has changed and whether the current treatment remains appropriate.
In other words, improvement should be measured rather than assumed.
Tirzepatide is a prescription medication, and its use for sleep apnea should be guided by a qualified healthcare provider.
There is more to treatment than simply deciding whether someone should take tirzepatide. A healthcare provider needs to consider the person's sleep apnea severity, weight, medical history, current medications, treatment goals, and response to therapy.
They can also monitor how the person is responding to treatment and address side effects. In the SURMOUNT OSA trials, the most commonly reported side effects were gastrointestinal, including symptoms such as nausea, diarrhea, and vomiting. Most were mild to moderate.
Medical guidance is especially important for people who are already using CPAP or another sleep apnea treatment. Changing or stopping sleep apnea treatment without professional advice can leave the condition inadequately treated.
A healthcare provider can help determine whether tirzepatide should be used as part of an overall treatment plan rather than treated as a replacement for appropriate sleep apnea care.
The FDA approval for obstructive sleep apnea applies to adults with obesity and moderate to severe obstructive sleep apnea.
That does not mean tirzepatide should automatically be used for every person with sleep apnea.
Someone with sleep apnea who does not have obesity may need a different treatment approach. This is another reason why treatment decisions should be based on an individual medical evaluation.
The newer research gives people with obesity and obstructive sleep apnea another treatment option. Tirzepatide has been shown to reduce the frequency of breathing disruptions during sleep and improve several measures associated with sleep apnea.
At the same time, it is important to keep expectations realistic.
Tirzepatide is not a quick fix for sleep apnea. It should not be started, stopped, or adjusted without medical guidance. It also should not be assumed that improvement in weight automatically means that sleep apnea has been cured.
For someone with obesity and moderate to severe obstructive sleep apnea, tirzepatide may become an important part of a broader treatment plan. Working with a healthcare provider allows treatment to be adjusted based on the person's weight, symptoms, sleep study results, medications, and overall health.
So, can tirzepatide help with sleep apnea?
Yes. For adults with obesity and moderate to severe obstructive sleep apnea, clinical research has shown that tirzepatide can significantly reduce breathing interruptions during sleep and improve several measures of sleep apnea. It is also FDA approved for this specific use.
But the best results come from treating sleep apnea as a medical condition, not simply as a weight problem.
If you have sleep apnea and are considering tirzepatide, talk with your healthcare provider first. Your provider can determine whether it is appropriate for you, monitor your response, and help make sure that your sleep apnea continues to be properly treated.
Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., Bunck, M. C., Bednarik, J., & SURMOUNT OSA Investigators. (2024). Tirzepatide for the treatment of obstructive sleep apnea and obesity. New England Journal of Medicine, 391(13), 1193–1205.
Patil, S. P., Ayappa, I. A., Caples, S. M., Kimoff, R. J., Patel, S. R., & Malhotra, A. (2019). Treatment of adult obstructive sleep apnea with positive airway pressure: An American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 15(2), 335–343.
U.S. Food and Drug Administration. (2024, December 20). FDA approves first medication for obstructive sleep apnea. U.S. Food and Drug Administration.
